UPDATE: Regeneron Pharma (REGN) PT Raised to $450 at Barclays on 2Q Preview; 'Dupixent Sales Should be Fine'

(Updated - July 21, 2017 8:49 AM EDT)

Barclays raised its price target on Regeneron Pharma (NASDAQ: REGN) to $450.00 (from $400.00) while maintaining a Equalweight rating, ahead of the company's second earnings announcement on August 3rd.

Analyst Geoff Meachem notes modest expectations into U.S. Biopharmaceuticals industry second quarter earnings cycle, as FX headwinds have declined recently, providing upside to estimates for the second half of 2017, as well as 2018. Furthermore, sentiment in the industry has improved with a Republican controlled administration, despite challenged efforts around healthcare, resulting in the groups outperformance relative to the broad market in second quarter. According to the analyst, Dupixent sales should be fine.

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• Morgan Stanley Upgrades Macquarie Group Ltd. (MQG:AU) (MQBKY) to Overweight
• JPMorgan Upgrades Bank Jago Tbk PT (ARTO:IJ) to Overweight
• CIBC Upgrades Goeasy Ltd (GSY:CN) (EHMEF) to Outperformer